[{"id":"76c77ff7-c81e-43e4-ae4a-aaef8350e163","acronym":"COCOON","url":"https://clinicaltrials.gov/study/NCT06120140","created_at":"2023-11-07T16:14:24.835Z","updated_at":"2025-02-25T14:42:28.607Z","phase":"Phase 2","brief_title":"Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib","source_id_and_acronym":"NCT06120140 - COCOON","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib) • Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) • minocycline"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 02/16/2024","start_date":" 02/16/2024","primary_txt":" Primary completion: 11/07/2025","primary_completion_date":" 11/07/2025","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2025-02-14"}]